Retatrutide (10mg/20mg)

Price range: $169.00 through $299.00

Quick Overview Retatrutide is an investigational unimolecular triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is designed to enable integrated modulation of appetite signalling, insulin secretion, and energy expenditure in metabolic research models.

Quantity

Independent Certification

Each batch is verified through third-party analytical testing for accuracy and traceability

Discreet Shipping

Secure, unbranded packaging with controlled handling and fast domestic delivery

Research Use Only

Supplied strictly for laboratory research, analytical validation, and scientific investigation

Category:

Quick Overview

Retatrutide is an investigational unimolecular triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is designed to enable integrated modulation of appetite signalling, insulin secretion, and energy expenditure in metabolic research models.

Full Research Overview

Retatrutide (research code: LY3437943) represents a next-generation class of multi-receptor agonists engineered to simultaneously activate GLP-1, GIP, and glucagon receptors within a single molecular framework.

Activation of the GLP-1 receptor is associated with delayed gastric emptying and central appetite regulation via hypothalamic pathways. GIP receptor engagement contributes to glucose-dependent insulinotropic activity, enhancing pancreatic beta-cell responsiveness and supporting glycaemic regulation. The addition of glucagon receptor agonism introduces a distinct metabolic dimension, promoting increased energy expenditure, hepatic lipid oxidation, and thermogenic processes.

Read More

• Purity: ≥99% (High-Performance Liquid Chromatography verified)
• Form: Lyophilised powder
• Research Code: LY3437943
• Research Status: Phase 3 clinical investigation

1. Jastreboff, Ania M., et al.
“Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.”
The New England Journal of Medicine, 2023.
View Source

2. Frias, Juan P., et al.
“Efficacy and Safety of Retatrutide, a Triple Hormone Receptor Agonist, in Patients with Type 2 Diabetes.”
The Lancet, 2023.
View Source

This product is supplied strictly as a Research Use Only (RUO) material.
It is not approved by the Therapeutic Goods Administration (TGA) in Australia or the United States Food and Drug Administration (FDA) for human or veterinary use.
This product is not intended for human consumption, medical use, therapeutic application, or diagnostic purposes.
NŪ LABS does not provide:

  • Medical advice
  • Clinical recommendations
  • Dosage instructions
  • Treatment protocols
  • Reconstitution or administration guidance

All products are intended strictly for laboratory research, analytical validation, and scientific investigation purposes only.
Users are responsible for ensuring compliance with all applicable local regulations and research frameworks.

Australian-Based

Locally operated supply with domestic fulfilment and support

Transparent Supply

Clear documentation and traceable sourcing with no hidden processes

Batch Verification

Every product linked to a unique batch ID with direct verification access

Third-Party Tested

All analytical data generated by independent laboratories, not internal sources